RUNX1 and acute myeloid leukemia: In core binding factor acute myeloid leukemia (AML), which is defined by cytogenetic abnormalities either due to translocation (8;21) (q22; q22.1) or due to inversion (16) (p13.1; q22), ADAR2 is down-regulated due to the expression of RUNX1-ETO additional exon 9a fusion protein that exerts a dominant negative effect on ADAR2 transcription (Darwish et al., 2023; Guo et al., 2023).